The testimonials of our customers testify of IDDI's added values of a highly skilled services offering for clinical research.
"We really appreciate the work you (and the rest of the team behind the scenes) have done to make this possible. The fact that the system went live in approximately 40 days from finalized protocol has not been lost on me. This is a truly amazing feat!' and 'Well done, IDDI team! You are now officially PanOptimists together with us!'
Paul G. Chaney, President and CEO, PanOptica, Inc. , Bernardsville, NJ, USA
"I also wanted to mention that in my 12 years of CRA work this is the most helpful "helpdesk" I have ever come across. It makes my work so much easier."
Michelle Stanley, Consultant CRA, Beltas, Auckland, New Zealand
"We are truly grateful to all those who participated in this important study," said Jim Taylor, CEO of Oraya Therapeutics. "Our partnership with IDDI was of great benefit, particularly with respect to their responsiveness, their commitment to quality and precision, and their ability to meet our very ambitious timelines.
Jim Taylor, CEO Oraya Therapeutics, Newark, CA, USA
"IDDI is always flexible and responsive. They clearly outline the project timelines and budgets and stick to them; if issues arise they always communicate them quickly. All employees are knowledgeable in their area of expertise and the whole clinical trial process. They are proactive, provide solutions, and point out the pros and cons of proposed solutions so that the Sponsor can make an informed decision."
Kristine Curtiss, Executive Director, Clinical Operations, PanOptica, Bernardsville, NJ , USA
"IDDI has performed data management for our 2 phase I/II trials and I am very happy of this collaboration. Everyone at IDDI was very responsive and professional. Flexibility is a great asset of the team!"
Gaëlle Charier, Clinical Project Leader, Molecular Partners AG, Switzerland
"My interaction with IDDI staff have been through e-mails and teleconferences. They were prompt in calling into meetings, and responding to e-mails. They were quite flexible to AZ/IDMC requests. They were adept at pointing out risks that AZ had inadvertently overlooked, and would always offer solutions to mitigate the risks. The planning and actual meeting with the IDMC was hitch-free. IDDI staff was always very professional, and I would rate them 5 on a scale of 1 - 5."
Ugochi A Emeribe, Principal Statistician, Astrazeneca R&D, Wilmington, DE, USA.